- Home
- KLRS vs SACH Comparison
KLRS vs SACH Comparison
Compare KLRS & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- SACH
- Stock Information
- Founded
- KLRS 2019
- SACH 2010
- Country
- KLRS United States
- SACH United States
- Employees
- KLRS N/A
- SACH N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- SACH Real Estate Investment Trusts
- Sector
- KLRS Health Care
- SACH Real Estate
- Exchange
- KLRS Nasdaq
- SACH Nasdaq
- Market Cap
- KLRS 46.0M
- SACH 54.4M
- IPO Year
- KLRS N/A
- SACH 2017
- Fundamental
- Price
- KLRS $4.39
- SACH $1.21
- Analyst Decision
- KLRS Strong Buy
- SACH Hold
- Analyst Count
- KLRS 2
- SACH 4
- Target Price
- KLRS $23.00
- SACH $2.25
- AVG Volume (30 Days)
- KLRS 728.6K
- SACH 291.1K
- Earning Date
- KLRS 11-15-2025
- SACH 11-13-2025
- Dividend Yield
- KLRS N/A
- SACH 16.33%
- EPS Growth
- KLRS N/A
- SACH N/A
- EPS
- KLRS N/A
- SACH N/A
- Revenue
- KLRS N/A
- SACH N/A
- Revenue This Year
- KLRS N/A
- SACH N/A
- Revenue Next Year
- KLRS N/A
- SACH $7.74
- P/E Ratio
- KLRS N/A
- SACH N/A
- Revenue Growth
- KLRS N/A
- SACH N/A
- 52 Week Low
- KLRS $2.14
- SACH $0.80
- 52 Week High
- KLRS $24.15
- SACH $2.70
- Technical
- Relative Strength Index (RSI)
- KLRS 58.92
- SACH 47.42
- Support Level
- KLRS $3.49
- SACH $1.15
- Resistance Level
- KLRS $5.30
- SACH $1.35
- Average True Range (ATR)
- KLRS 0.77
- SACH 0.07
- MACD
- KLRS -0.01
- SACH -0.01
- Stochastic Oscillator
- KLRS 23.97
- SACH 27.50
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.